Antares Pharma, Inc. (ATRS)

[H2R]

Hi Frauddoc,

Based on your info, I checked the CC transcript:

And finally, AMAG reported the second quarter that the FDA had set their sNDA review period 10 months, which resulted in a target action date of February 14, 2018. We are currently executing on a purchase order for commercial devices for use in our Makena subcutaneous auto injector product as AMAG await FDA action on their sNDA.

Now about Epinephrine:

Turning now to epinephrine, we continue to ship pre-launch devices to Teva in the second quarter bringing the total dollar amount shipped to-date of approximately$20 million worth of devices. Teva's ANDA for this product is still under active review in the FDA. And Teva recently changed its guidance from approval in late 2017 or early 2018 due to potential for an early 2018 launch again pending FDA approval.

https://seekingalpha.com/article/4096418-antares-pharmas-atrs-ceo-bob-apple-q2-2017-results-earnings-call-transcript?part=single

And slide 15

https://seekingalpha.com/article/4096257-antares-pharma-inc-2017-q2-results-earnings-call-slides?part=single

So it looks like for the EpiPen it's a different story.

Lots in the pipeline!

Kind regards